Cellectis Announces The Closing Of The Sale Of Its Swedish Subsidiary Cellectis AB To Takara Bio
PARIS--(BUSINESS WIRE)--Regulatory News: Cellectis (Alternext: ALCLS.PA) (Paris:ALCLS) a leader in the development of adoptive immunotherapies based on engineered allogeneic CART cells (UCART) today announces that it has closed the sale of its subsidiary Cellectis AB to Takara Bio Inc. The financials terms have not been disclosed.
Help employers find you! Check out all the jobs and post your resume.